Judge allows sales of Momenta drug copy

Bloomberg News/File

Momenta gets revenue from generic Lovenox sold by partner Novartis AG’s Sandoz unit.

Shares of Momenta Pharmaceuticals Inc., a Cambridge company that owns patents on the blood-thinner Lovenox, fell after a court cleared the way for Watson Pharmaceuticals to sell a generic version of the drug. The US Court of Appeals for the Federal Circuit granted Watson partner Amphastar Pharmaceuticals a stay of an order that prevented sales. A US judge in Boston blocked sales of the drug copy, saying Momenta was likely to win a patent-infringement suit it had filed. The Federal Circuit said its order “does not represent a final decision’’ on the merits of the appeal.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of